Welcome back to another AJMC Insights series. In this episode titled, 'Setting the Stage: Treatment Selection and Eligibility in Follicular Lymphoma,' Ryan Haumschild, PharmD, MS, MBA, CPEL led the conversation about the following questions: 1. What are the first-line treatment options in follicular lymphoma? 2. When are you considering a patient eligible for later lines of therapy?
How payers curb inappropriate ATTR-CM therapy use with better scans, prior auth, real-world outcomes, and telemedicine to speed access.
Experts weigh prior authorization, step therapy, and 12‑month coverage to balance access and cost for high‑value long‑term therapies.
Real-world evidence and claims data compare amyloidosis therapies, linking outcomes and symptom burden to total cost of care.
In this episode, ‘Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making,’ the panelists explore the key clinical and economic considerations that drive therapy selection across the three available ATTR-CM treatments. Dr. Alexander opens by emphasizing shared decision-making as a foundational principle, noting that in the absence of head-to-head data, patient preferences carry significant weight alongside clinical judgment. He outlines several practical factors influencing treatment choice, including route of administration, as vutrisiran is a quarterly injection given in a healthcare setting, acoramidis is a twice-daily oral pill, and tafamidis is a once-daily oral pill, each presenting distinct advantages depending on patient circumstances such as pill burden or transportation access.
Long-term ATTR-CM trial data show durable benefits with early tafamidis or acoramidis, fewer deaths/hospitalizations, and manageable safety.
Learn how TTR stabilizers and gene silencers curb amyloid buildup in ATTR-CM, with trial evidence for fewer hospitalizations and better survival.
Experts discuss the promising advancements in HER2-mutant lung cancer treatments, emphasizing the importance of molecular testing and clinical trials.
Emerging HER2-targeted therapies in lung cancer highlight the importance of real-world data and survival metrics for patient outcomes and treatment access.
Pharmacists play a vital role in oncology, enhancing patient care through medication management, education, and support for novel therapies.
This episode examines the barriers to accessing HER2-targeted therapies for non-small cell lung cancer (NSCLC) and strategies to overcome them. The discussion highlights the importance of aligning with payer requirements and clinical guidelines, such as those from NCCN, to facilitate insurance approval of recently FDA-approved HER2-targeted treatments.
Experts discuss the FDA's Accelerated Approval Program, emphasizing its role in providing earlier access to innovative cancer therapies for patients.
Experts discuss the promising future of HER2-targeted therapies, highlighting new treatments and combination strategies for non-small cell lung cancer.
Experts discuss the potential of TKIs like zongertinib and seviberatinib as first-line treatments for HER2-mutant non-small cell lung cancer.
Explore the significance of patient-reported outcomes in cancer treatment, highlighting the benefits of zongertinib and its impact on quality of life.
Dr. Hirsch discusses the promising efficacy and safety of cevertinib for HER2-mutant non-small cell lung cancer, highlighting its potential as a first-line treatment.
Discover the latest insights on Zongertinib's efficacy and safety for HER2-mutant non-small cell lung cancer, promising new treatment options.
Explore the differences between emerging HER2-targeted TKIs, Zongertinib and Seviberatinib, and their therapeutic implications in cancer treatment.
Explore the latest HER2-targeted therapies for non-small cell lung cancer, including treatment options and patient-centered decision-making strategies.
Timely initiation of targeted therapy is crucial for improving cancer outcomes and patient quality of life, especially for those with HER2 mutations.
Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and treatment access.
Experts explore HER2 mutations and the critical role of comprehensive molecular profiling in optimizing treatment for non-small cell lung cancer patients.
Panelists discuss how defining and tracking meaningful real-world outcomes ensures accountability and value in MASH management.
Panelists discuss how multidisciplinary collaboration is essential for preventing progression and improving outcomes in MASH care.
Panelists discuss how noninvasive risk assessments enable early detection and targeted management of fibrosis in MASH patients.
Panelists discuss how patients express satisfaction with digital therapeutics for their convenience and real-time accessibility, though lack of payer coverage limits the ability to gather meaningful real-world evidence on their effectiveness.
Panelists discuss how CT-155, a 16-week interactive digital application, met its primary end point in clinical trials by successfully improving experiential symptoms of schizophrenia compared with a control app, with an excellent safety profile.
Panelists discuss how integrating clinical efficacy with cost-effectiveness ensures sustainable adoption of MASH therapies.
